← board
NAII
distress 2/10 · well-funded / low risk$2.39+0%today-51% from 52w high
Revenue
pre-revenue
Liquidity
$9M
Runway
—
Shares 1y
+2%
Price & events
-44.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.4%
1D
+5.8%
1W
-3.6%
1M
-13.4%
3M
-42.4%
6M
-34.5%
1Y
-58.7%
2Y
-85.9%
5Y
-77.5%
All
Overview
- Market Cap
- $15.00M
- Volume
- 567
- 52 Week Range
- $2.15 – $4.83
- Total Shares
- 6.28M
- Float Shares
- 4.93M
- Short %
- 0.13%
- % Held by Insiders
- 21.68%
- % Held by Institutions
- 34.98%
- RVOL
- 0.02x
- Beta
- 0.36
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2025-07-16partnershipManufacturing agreement with Juice Plus+ Company for 24 countries, initial term ending July 16, 2027.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.